We are delighted to announce the initiation of a Phase II and Phase III randomized clinical trial, using the method of mEHT as a treatment for breast cancer patients.
The trial, performed with the Oncotherm EHY-2030 device, is being conducted in the Division of Oncology, Department of Internal Medicine and Oncology at Semmelweis University in Hungary under the coordination of Dr. Marcell Szász, with Prof. Magdolna Dank serving as the principal investigator.
The aim of the study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with triple negative/basal-like and luminal B (all neoadjuvantly treated HER2-negative), stage II-III breast cancer.
The trial began recently and is expected to run until the end of 2024. However, due to the extensive data analysis and interpretation required, the estimated completion date for this study is in April 2025. By involving 120 participants, the phase III trial represents a significant step forward in breast cancer research, as it evaluates the treatment approach and holds the potential to redefine treatment protocols and improve patient outcomes.
We truly appreciate the researchers, clinicians, and participants involved in this trial and eagerly anticipate the forthcoming conclusion!
